The 2025 federal tax law let businesses deduct domestic research costs right away again under new Section 174A. States don’t all follow it. This table shows each state’s 2026 treatment of research expensing and whether it offers its own R&D credit.
Get a Free R&D Credit Review
Tell us about your business and a specialist from our partner network will follow up.
"*" indicates required fields
Short answer: as of November 2026, 23 states follow federal Section 174A immediate expensing, while others require amortization, add-backs or have not issued guidance. 38 states offer their own research credit on top of the federal credit.
Why Section 174A Conformity Matters
Federal law now lets you deduct domestic research and experimental costs in the year you pay them, for tax years beginning after 2024. A state that decouples makes you add some or all of that deduction back and amortize it, often over five years. That doesn’t affect the federal R&D tax credit, but it can raise your state tax bill in the early years.
2026 State Section 174A and R&D Credit Table
| State | Section 174A treatment | Details | State R&D credit |
|---|---|---|---|
| Alabama | Conforms (immediate expensing) | Conforms for tax years beginning after Dec. 31, 2024 (corporations §40-18-33; individuals §40-18-13(a)). Act 2025-400 (HB 163) decoupled from TCJA §174 for tax years beginning on or after Jan. | No |
| Alaska | Conforms (immediate expensing) | Conforms (rolling IRC adoption). | Yes: Corporations only: 18% of the federal research credit attributable to Alaska (apportioned), on Form 6390. Nonrefundable; |
| Arizona | No state guidance found | ADOR 2025 forms assume the Legislature adopts federal changes made after Jan. 1, 2025; enactment of 2025 conformity legislation and any 174A decoupling not verified. | Yes: 24% of first $2.5M of Arizona QREs over base, 15% above (tax years beginning before Dec. 31, 2030; 20%/11% after); |
| Arkansas | No state guidance found | No DFA guidance on §174A found. DFA states P.L. 119-21 provisions have not been adopted (in the §179 context). | Yes: In-house 20% of QREs above prior-year baseline; targeted business 33% for 5 years (sellable once); strategic value 33% up to $50,000/yr; |
| California | Decoupled | Does not adopt §174A (IRC date Jan. 1, 2025 predates OBBBA) and did not adopt TCJA §174 amortization (SB 711 lists TCJA §13206(a) “Amortization of Research and Experimental Expenditures” as not conformed). | Yes: 15% of CA QREs over base (regular) or, from 2025, ASC at 3% (1.3% with no prior QREs); 24% of basic research payments (corporations). AIC repealed. |
| Colorado | Conforms (immediate expensing) | Conforms (rolling). HB26-1222 add-back lost. | Yes: Enterprise zone only: 3% of in-zone R&E expenditures above the 2-prior-year in-zone average; 25% of the credit allowed per year over 4 years; |
| Connecticut | Requires amortization | CBT conformity to §174A delayed one year: for income years 2022-2025 the deduction follows §174 as in effect July 3, 2025 (5-year domestic amortization), and the OBBBA §70302(f) catch-up deduction is disallowed. | Yes: Corporations: 20% incremental credit (CGS 12-217j) and non-incremental credit (12-217n) of 6% for qualified small businesses (gross income <= $100M)… |
| Delaware | Conforms (immediate expensing) | Conforms to §174A expensing for tax years 2025 and later. Corporations are decoupled from OBBBA’s retroactive relief for 2022-2024 capitalized costs, which keep the TCJA amortization schedule (TIM 2025-2; 30 Del. C. §1903(d)(1)). | Yes: Elect 10% of Delaware QREs above a Delaware base amount, or 50% of Delaware’s apportioned share of the federal ASC; small businesses (avg. |
| Florida | Requires amortization | Decoupled: Florida excludes §174A and keeps §174(a) as in effect Jan. 1, 2025, so domestic research costs are amortized over 5 years for Florida; recompute federal taxable income on a pro forma return | Yes: 10% of Florida QREs above the 4-year average base; corporations in target industries only; capped at 50% of remaining corporate income tax; |
| Georgia | Decoupled | Georgia does not adopt §174A but applies pre-TCJA §174 (SB 56, 2023, tax years from 2022), so R&E costs are fully deductible in the year paid or incurred; HB 1199 kept this. | Yes: 10% of Georgia QREs above a base (Georgia gross receipts x lesser of 3-yr average research ratio or 0.300); |
| Hawaii | Requires amortization | Decoupled from §174A; keeps §174 as in effect Dec. 31, 2024 (5-year amortization of domestic R&E) under HB 2329 (2026). | Yes: Refundable credit for qualified high technology businesses (≤500 employees, >50% of activities in Hawaii research): the federal §41 credit times the… |
| Idaho | Conforms (immediate expensing) | Conforms to §174A for domestic R&E incurred in 2025 and later; does not adopt the OBBBA transition rules for 2022-2024 costs (they stay on the 5-year schedule). | Yes: 5% of Idaho QREs over an Idaho base amount plus 5% of Idaho basic research payments; no ASC; nonrefundable; 14-year carryforward; Form 67. |
| Illinois | Conforms (immediate expensing) | Conforms for 2025 and 2026: Illinois is a rolling-conformity state and neither S.B. 1911 (P.A. 104-0453) nor the 35 ILCS 5/203 addition modifications decouple from IRC 174A (Section 203 addbacks reach 168(k)/168(n) only). | Yes: 6.5% of Illinois QREs above the prior 3-year average; nonrefundable; 5-year carryforward; available for tax years ending before Jan 1, 2037 (P.A. |
| Indiana | Conforms (immediate expensing) | Conforms (and more generous). Tax year 2025 and later: no Indiana addback for domestic R&E deducted under IRC 174A; foreign R&E (still amortized federally) is fully deductible for Indiana with the federal amortization added back. | Yes: 15% of Indiana QREs over base up to $1M + 10% above $1M, or alternative 10% of QREs over 50% of 3-yr average (5% if no QREs in any of the 3 prior… |
| Iowa | Conforms (immediate expensing) | Conforms for 2025 and 2026: Iowa’s rolling conformity picks up §174A immediate domestic R&E expensing. No 2025 or 2026 decoupling bill was found (the 2026 SF 2492 addressed NCTI only). | Yes: 2025: Research Activities Credit 6.5% regular / 4.55% ASC, 70% of excess refundable; |
| Kansas | Conforms (immediate expensing) | Conforms for TY2025 and TY2026. Kansas starts from federal income under rolling conformity, so §174A immediate domestic R&E expensing (and the transition elections) flows through. No 2025 or 2026 Kansas decoupling bill was found. | Yes: 10% of Kansas R&D spending above the 3-year average (current + 2 prior years); only 25% usable per year; unlimited carryforward; |
| Kentucky | Requires amortization | Tax years beginning on/after Jan. 1, 2026 (HB 757 + HB 869): add back §174A deduction, subtract 5-year amortization under §174 as of Dec. 31, 2024. For 2025, conformity date Dec. 31, 2024 (pre-OBBBA), so TCJA amortization applied. | Yes: Qualified Research Facility credit only: 5% of qualified costs to construct, remodel, expand or equip Kentucky research facilities (tangible… |
| Louisiana | Conforms (immediate expensing) | Elective Louisiana “bonus amortization” deduction lets research and experimental expenditures (IRC 174 as of Jan. 1, 2024) paid or incurred on or after Jan. 1, 2025 be deducted in the year incurred (R.S. 47:287.744(D), 47:297.25). | Yes: 30% (<50 employees), 10% (50–99) or 5% (100+) of LA QREs above a base (50% or 80% of 3-yr average); 30% of SBIR/STTR awards; |
| Maine | Requires amortization | Tax years 2025-2029: add back the §174A deduction times 100% (2025), 70% (2026), 50% (2027), 30% (2028), 10% (2029); recapture ratably through tax years beginning in 2030. | Yes: 5% of Maine QREs above the prior 3-year average plus 7.5% of basic research payments (36 M.R.S. §5219-K); |
| Maryland | Decoupled | Automatically decoupled from §174A(a) for tax years beginning in 2025 and from the §174A transition rules for earlier years: 2025 and prior domestic R&E stays on 5-year amortization, add-back on Form 500DM, no amended returns to… | Yes: 10% of Maryland QREs above the Maryland base amount; $250,000 per applicant; $12M statewide ($3.5M small-business set-aside); |
| Massachusetts | Conforms (immediate expensing) | Decoupled for tax years beginning in 2025 (deduct under §174 as in effect July 3, 2025, i.e. 5-year amortization); disallowance repealed and §174A followed for tax years beginning on or after Jan. 1, 2026 (H. 5470 / TIR 26-4). | Yes: 10% of MA QREs above base (regular or ASC; ASC 5% if no QREs in prior 3 years) plus 15% of basic research payments; corporate excise only; |
| Michigan | Decoupled | Decoupled for tax years beginning after Dec 31, 2024 (2025 and 2026): compute Michigan income as if domestic R&E must be amortized over 5 years; | Yes: Refundable credit from 2025: 3% of Michigan QREs up to base + 10% above (250+ employees, $2M cap) or 15% above (<250 employees, $250K cap); |
| Minnesota | Partial add-back | Split by entity type (Laws 2026 ch. 128, retroactive). Individuals, partnerships, S corporations, estates and trusts conform to §174A expensing for 2025 and 2026. | Yes: 10% of the first $2M of QREs over the base, 4% above; no ASC; partially refundable from 2025 (19.2% in 2025, 25% in 2026-2027); 15-year carryforward |
| Mississippi | Conforms (immediate expensing) | Effectively conforms: since tax years beginning after Dec. 31, 2022, Mississippi lets taxpayers deduct specified R&E expenditures immediately or elect §174 amortization (HB 1733). No DOR guidance naming §174A found. | No |
| Missouri | Conforms (immediate expensing) | Conforms for TY2025 and TY2026. Rolling conformity (RSMo 143.091), and no §174/§174A modification in RSMo 143.121 (current version effective Aug. 28, 2025). | Yes: 15% of additional QREs over the prior 3-year average (20% with a Missouri college/university); $300,000 per taxpayer, $10M statewide ($5M reserved); |
| Montana | Conforms (immediate expensing) | Conforms in practice (federal taxable income starting point; no decoupling enacted). | No |
| Nebraska | Conforms (immediate expensing) | Conforms for TY2025 and TY2026 (rolling); DOR scores R&E expensing as a revenue loss of $10.1M in FY2025-26. | Yes: 15% of the federal §41 credit (35% for research on a Nebraska college/university campus or facility); |
| Nevada | No income tax | n/a (no income tax). | No |
| New Hampshire | Requires amortization | Inferred: BPT uses the IRC as of Dec. 31, 2018, which predates §174A, so pre-OBBBA §174 amortization would apply. No DRA guidance retrieved (revenue.nh.gov blocked). Confirm with DRA. | Yes: 10% of qualified manufacturing R&D wages above the IRC §41 base (minimum base may be 0), against BPT; per-taxpayer cap $50,000 ($100,000 from Jan. |
| New Jersey | Conforms (immediate expensing) | CBT starts from federal taxable income and follows the federal (OBBBA) timing for non-NJ research costs; NJ QREs used for the NJ credit are deducted in the same year as the credit under N.J.S.A. 54:10A-4(k)(11) (TB-114, rev. Nov. | Yes: 10% of NJ QREs over the base (same method as federal, regular or ASC) + 10% of NJ basic research payments; CBT only; |
| New Mexico | Conforms (immediate expensing) | Base income starts from federal taxable income; SB 151 (2026) decoupled only from 168(k), 168(n) and the 163(j) change, not from §174A. | Yes: Technology Jobs and R&D credit: basic 5% of qualified expenditures (10% rural); additional 5% (10% rural) against income tax with $75,000 payroll… |
| New York | Requires amortization | Decoupled for tax years beginning on or after Jan. 1, 2025: domestic and foreign R&E amortized over 60 months (state). NYC: domestic R&E incurred on or after Jan. 1, 2025 amortized over 5 years; foreign stays on 15 years. | Yes: No general R&D credit. Program credits: Excelsior R&D component = 50% of federal credit attributable to NY expenditures, capped at 6% of NY QREs (7%… |
| North Carolina | Decoupled | Decoupled: add back 80% of §174A(a) deduction; deduct 25% of add-back in each of next 4 years. D-400 Sch S Part A line 15 / Part B line 40; CD-405 Sch H line 1(h) / 3(g); NC-PE Part A line 15 | No |
| North Dakota | Conforms (immediate expensing) | Conforms for tax years 2025 and 2026: rolling conformity means §174A immediate domestic R&E expensing (and the 2022-2024 small-business catch-up) flows into ND taxable income. | Yes: 25% of the first $100,000 of ND QREs over the base, 8% above that (ASC option 17.5% / 5.6%); 3-year carryback, 15-year carryforward; |
| Ohio | Conforms (immediate expensing) | CAT: irrelevant (gross receipts tax, no expense deductions). Personal income tax (pass-through owners and sole props): conforms for 2025 and 2026. Ohio starts from federal AGI; S.B. | Yes: Nonrefundable CAT credit of 7% of Ohio QREs above the prior 3-year average (ORC 5751.51); 7-year carryforward; |
| Oklahoma | No state guidance found | No OTC guidance on §174A found; the 2025 Schedule 511-B lists no add-back for research or experimental costs. | No |
| Oregon | Conforms (immediate expensing) | Conforms (SB 1507 moves to IRC as of Dec. 31, 2025 and does not decouple from §174A). | Yes: Semiconductor companies only: 15% of Oregon QREs over the §41 base, up to $4M per taxpayer a year, Business Oregon certification each year, biennial… |
| Pennsylvania | Decoupled | CNIT (Act 45 of 2025): add back federal R&E deductions under 174/174A/59(e)/481 and deduct 20% a year over 5 years, for tax years beginning after Dec. 31, 2024; remaining 2022-24 amounts amortized 20% a year from 2025. | Yes: 10% of PA QREs over the PA base (20% for small businesses with under $5M net book assets); |
| Rhode Island | Requires amortization | Decoupled from OBBBA §174A for 2025 (Division Advisory 2025-18, RI Schedule 174A, temporary); FY2027 budget (H 7127, signed June 12, 2026) makes it permanent for tax years beginning on or after Jan. | Yes: 22.5% of the first $111,111 of excess QREs (first $25,000 of credit), 16.9% above; plus 10% R&D property credit; capped at 50% of tax; |
| South Carolina | Requires amortization | Not adopted under the posted Dec. 31, 2024 IRC date; pre-OBBBA §174 amortization applies for SC (inference; no SCDOR guidance found) | Yes: 5% of SC qualified research expenses (§41 definition), must claim federal §41 credit; capped at 50% of remaining tax; carryforward up to 10 years; |
| South Dakota | No income tax | Moot for tax years 2025 and 2026: no income tax, so federal §174A expensing has no state effect for general businesses. (Financial institutions under the bank franchise tax start from federal taxable income; | No |
| Tennessee | Conforms (immediate expensing) | Since tax years beginning on or after Jan. 1, 2022, Tennessee applies pre-TCJA §174 for excise tax (immediate deduction of R&D expenditures, Public Chapter 743 (2022), Notice #22-03), so domestic expensing under §174A matches the… | No |
| Texas | No income tax | No income tax. Franchise tax margin uses federal-return amounts under current federal law from 2026 reports; no Comptroller guidance on 174A by name. | Yes: 8.722% of Texas QREs above 50% of 3-year average (10.903% with a Texas higher-ed contract); 4.361%/5.451% if no QREs in a prior period; |
| Utah | Conforms (immediate expensing) | Rolling conformity. 2026 H.B. 587 would have required add-back/amortization; not enacted (no enrolled bill). | Yes: 5% of Utah QREs above base + 5% of basic research payments above base (14-yr carryforward) + 7.5% of current-year Utah QREs (no carryforward); |
| Vermont | Requires amortization | Taxpayers that are not small businesses under §448(c) add back the §174A deduction and deduct amortization under §174 as in effect Dec. 31, 2024 (5 years domestic). | Yes: 27% of the federal §41 credit attributable to Vermont research (75% from Jan. 1, 2027 under Act 164 of 2026); against Vermont income tax; |
| Virginia | Requires amortization | Decoupled from immediate domestic R&E expensing, including retroactive and catch-up provisions; costs stay on the prior amortization schedule, with fixed date conformity additions/subtractions (HB 29, TB 26-1) | No |
| Washington | No income tax | n/a (no income tax today; ESSB 6346 rules for 2028 not yet published). | No |
| West Virginia | Conforms (immediate expensing) | Conforms: 2026 conformity bills give effect to OBBBA amendments; Governor’s office cites reinstated full expensing of domestic R&D | No |
| Wisconsin | Decoupled | Wisconsin did not adopt OBBBA §70302 (§174A) or the TCJA §174 capitalization (P.L. 115-97 §13206). | Yes: 5.75% of WI QREs over 50% of prior-3-year average (2.875% of all QREs if no QREs in a prior year); |
| Wyoming | No income tax | n/a (no income tax). | No |
Frequently Asked Questions
Do states follow Section 174A?
Not all of them. Some states adopted federal immediate expensing, others require a 5-year amortization or an add-back, and some have not issued guidance yet.
Does state decoupling change my federal R&D credit?
No. The federal credit and the federal Section 174A deduction are the same regardless of state. Only the state return changes.
Which states have their own R&D tax credit?
As of November 2026, 38 states offer their own research credit. Rates, caps and refundability vary widely; see each state guide in the table.
Can I claim a state R&D credit without the federal credit?
Most state credits use federal Section 41 definitions, so the same documentation supports both. Some states require pre-approval or an application before the return is filed.
See what your business qualifies for. One free review covers cost segregation, R&D, hiring credits and benefits savings together. Call 360-641-7709 or use the button below.
Last updated November 2, 2026. Reviewed after each state legislative session. This page is general information, not tax or legal advice. Confirm your situation with a qualified tax professional.
Sources: each state guide linked in the table cites that state’s revenue department guidance and legislation. See also our Section 174A guide and state R&D tax credits.